Heptares Therapeutics, a biotech spin-out from Cambridge University, has received $21m in a series B round that opens the door to clinical trials. Launched in 2007 after three years in incubation, the Welwyn Garden City-based spin-out is commercialising treatments for schizophrenia and Alzheimer’s developed at Cambridge’s Medical Research Council (MRC) Laboratory of Molecular Biology, which…
Heptares gets clinical with $21m
Jul 3, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024